Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Extends Review Period for Quizartinib in AML

April 4th 2019

The FDA has added 3 months to the review period for a new drug application for quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia, allowing the agency to review additional data provided by Daiichi Sankyo.

Novel Therapies Reduce Symptom Burden, Result in Improved Survival in MPNs

April 4th 2019

Terrence J. Bradley, MD, discusses approved and investigational agents that patients with myelofibrosis and polycythemia vera can turn to.

Expert Provides Guidelines for Diagnosis and Management of TA-TMA

April 3rd 2019

While complex, criteria for diagnosing transplant-associated thrombotic microangiopathy following hematopoietic stem cell transplantation should be closely followed and should begin with screening.

Cyclophosphamide-Driven Efficacy in GVHD Unaffected by Matched Unrelated Donor Status

April 3rd 2019

Cyclophosphamide administered alone or in combination with other agents is an effective prophylactic treatment for graft-versus-host disease, regardless of stem cell source, conditioning intensity, or patient age in 10/10 and 9/10 human leukocyte antigen matched unrelated donor hematopoietic stem cell transplantation recipients.

Risk Factor Profile Determined for Development of Pediatric TA-TMA After HSCT

April 3rd 2019

The development of high-grade acute graft-versus-host disease following hematopoietic stem cell transplantation poses the highest risk for transplant-associated thrombotic microangiopathy in pediatric patients.

Salvage Daratumumab Reaches High ORR in Relapsed Myeloma Following Allogeneic SCT

April 2nd 2019

Patients with multiple myeloma who relapsed following allogeneic stem cell transplantation and also failed several posttransplant therapies demonstrated a strong response to daratumumab salvage therapy.

Dr. Hoffman on Anticipated Developments in Multiple Myeloma

April 2nd 2019

James E. Hoffman, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses anticipated developments in the field of multiple myeloma.

Gilteritinib Improves OS in Relapsed/Refractory FLT3+ AML

April 1st 2019

Gilteritinib was found to significantly improve overall survival in patients with relapsed/refractory FLT3 mutation–positive acute myeloid leukemia, according to updated findings of the phase III ADMIRAL trial.

Umbralisib Achieves Impressive ORR in Relapsed/Refractory MZL

April 1st 2019

The PI3K-delta inhibitor umbralisib was found to demonstrate an overall response rate of 52% and show an encouraging tolerability profile in patients with relapsed/refractory marginal zone lymphoma, according to findings from a cohort of the phase IIb UNITY-NHL trial.

Ruxolitinib/Etanercept Combo Resolves Steroid-Refractory Acute GVHD Following Allogeneic SCT

April 1st 2019

A novel treatment of ruxolitinib combined with etanercept led to encouraging response and survival rates in patients who developed grades 3/4 steroid-resistant acute graph-versus-host disease after undergoing allogeneic stem cell transplantation.

Dr. Bradley on Ruxolitinib in Myeloproliferative Neoplasms

March 30th 2019

Terrence J. Bradley, MD, assistant professor, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami in Health System, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms (MPNs).

Treosulfan Conditioning Regimen for Allogeneic HSCT Improves Survival for MAC-Ineligible AML, MDS

March 27th 2019

Treosulfan added to fludarabine demonstrated an improvement in event-free and overall survival compared with busulfan/fludarabine as a treatment for patients with acute myeloid leukaemia or myelodysplastic syndrome who are scheduled for allogeneic hematopoietic stem cell transplantation but are considered ineligible for standard myeloablative conditioning.

FDA Grants Breakthrough Designation to Ivosidenib Combo for Newly Diagnosed IDH1+ AML

March 27th 2019

The FDA has granted a breakthrough therapy designation to the combination of ivosidenib and azacitidine for the treatment of newly diagnosed patients with IDH1-mutant acute myeloid leukemia ≥75 years old or are ineligible for intensive induction chemotherapy.

Moskowitz Weighs Benefits, Challenges With A+AVD in Hodgkin Lymphoma

March 25th 2019

Craig Moskowitz, MD, discusses the role of PET imaging in the treatment of patients with Hodgkin lymphoma, weighs the pros and cons of A+AVD, and speaks to where future research is headed in the space.

AML Armamentarium Expands, Offering Hope for Consistent Cure

March 25th 2019

Justin M. Watts, MD, sheds light on these promising agents and their impact in the space, discusses remaining challenges, and expresses his hope for an era where most patients with acute myeloid leukemia will be cured.

Nimer Highlights Treatment Trends Across Hematologic Malignancies

March 25th 2019

Stephen D. Nimer, MD, sheds light on new strategies and trends in the treatment of patients with hematologic malignancies.

TKI Discontinuation Criteria Established in Updated NCCN CML Guideline

March 23rd 2019

With careful monitoring, discontinuation of TKI therapy is considered safe in adult patients with chronic myeloid leukemia in the chronic phase, who achieve and maintain a major molecular response.

Dr. Cho on Promising Combinations in Multiple Myeloma

March 20th 2019

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses promising combinations in multiple myeloma.

Dr. Holstein on BiTEs in Multiple Myeloma

March 19th 2019

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska Medical Center, discusses the emergence of bispecific T-cell engagers (BiTEs) in multiple myeloma.

Quizartinib Data Move FLT3 Inhibition Forward in AML Paradigm

March 19th 2019

FLT3 inhibition continues to be explored as a therapeutic option for patients with FLT3-mutant acute myeloid leukemia, with quizartinib at the forefront following intriguing results of the phase III QuANTUM-R trial.